However, the use of CTLA-4 checkpoint inhibitors has been complicated by the emergence of autoimmunity, including demyelination.1 We report the first case of biopsy-proven central nervous system (CNS) inflammatory demyelination in the context of primary immunodeficiency and a novel CTLA-4 variant. The gene discussed is CTLA4; the disease is inborn error of immunity.